Antiviral drug (nirmatrelvir/ritonavir) – Paxlovid™

Updated October 24, 2025

Oral antiviral drug Paxlovid™ (nirmatrelvir/ritonavir) is indicated to reduce the risk of hospitalization in adults with mild to moderate COVID-19 at high risk of progressing to severe COVID-19. It is indicated for adults who are moderate-to-severely immunocompromised, and/or 60 years or older with a high-risk chronic condition. 

For details, see: 

• Paxlovid – information for health professionals 
• BCPhA Paxlovid™ Resources for Pharmacists 
• COVID-19 Treatment – Health Care Provider Information  
• BCCDC: Treatments  

Public-facing links: 

• Paxlovid for B.C. residents 
• COVID-19 testing and treatments  
• Patient information FAQ for Paxlovid